177 related articles for article (PubMed ID: 28196613)
1. Potent and Selective EphA4 Agonists for the Treatment of ALS.
Wu B; De SK; Kulinich A; Salem AF; Koeppen J; Wang R; Barile E; Wang S; Zhang D; Ethell I; Pellecchia M
Cell Chem Biol; 2017 Mar; 24(3):293-305. PubMed ID: 28196613
[TBL] [Abstract][Full Text] [Related]
2. NMR-Guided Design of Potent and Selective EphA4 Agonistic Ligands.
Baggio C; Kulinich A; Dennys CN; Rodrigo R; Meyer K; Ethell I; Pellecchia M
J Med Chem; 2021 Aug; 64(15):11229-11246. PubMed ID: 34293864
[TBL] [Abstract][Full Text] [Related]
3. Antisense-mediated reduction of EphA4 in the adult CNS does not improve the function of mice with amyotrophic lateral sclerosis.
Ling KK; Jackson M; Alkam D; Liu D; Allaire N; Sun C; Kiaei M; McCampbell A; Rigo F
Neurobiol Dis; 2018 Jun; 114():174-183. PubMed ID: 29518482
[TBL] [Abstract][Full Text] [Related]
4. The identification of a novel isoform of EphA4 and ITS expression in SOD1
Zhao J; Boyd AW; Bartlett PF
Neuroscience; 2017 Apr; 347():11-21. PubMed ID: 28153688
[TBL] [Abstract][Full Text] [Related]
5. Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis.
Rué L; Oeckl P; Timmers M; Lenaerts A; van der Vos J; Smolders S; Poppe L; de Boer A; Van Den Bosch L; Van Damme P; Weishaupt JH; Ludolph AC; Otto M; Robberecht W; Lemmens R
Acta Neuropathol Commun; 2019 Jul; 7(1):114. PubMed ID: 31300041
[TBL] [Abstract][Full Text] [Related]
6. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans.
Van Hoecke A; Schoonaert L; Lemmens R; Timmers M; Staats KA; Laird AS; Peeters E; Philips T; Goris A; Dubois B; Andersen PM; Al-Chalabi A; Thijs V; Turnley AM; van Vught PW; Veldink JH; Hardiman O; Van Den Bosch L; Gonzalez-Perez P; Van Damme P; Brown RH; van den Berg LH; Robberecht W
Nat Med; 2012 Sep; 18(9):1418-22. PubMed ID: 22922411
[TBL] [Abstract][Full Text] [Related]
7. Reducing EphA4 before disease onset does not affect survival in a mouse model of Amyotrophic Lateral Sclerosis.
Rué L; Timmers M; Lenaerts A; Smolders S; Poppe L; de Boer A; Van Den Bosch L; Van Damme P; Robberecht W; Lemmens R
Sci Rep; 2019 Oct; 9(1):14112. PubMed ID: 31575928
[TBL] [Abstract][Full Text] [Related]
8. Decreased signalling of EphA4 improves functional performance and motor neuron survival in the SOD1
Zhao J; Cooper LT; Boyd AW; Bartlett PF
Sci Rep; 2018 Jul; 8(1):11393. PubMed ID: 30061574
[TBL] [Abstract][Full Text] [Related]
9. Dynamic principle for designing antagonistic/agonistic molecules for EphA4 receptor, the only known ALS modifier.
Qin H; Lim LZ; Song J
ACS Chem Biol; 2015 Feb; 10(2):372-8. PubMed ID: 25334011
[TBL] [Abstract][Full Text] [Related]
10. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism.
Cervetto C; Frattaroli D; Maura G; Marcoli M
Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure and NMR binding reveal that two small molecule antagonists target the high affinity ephrin-binding channel of the EphA4 receptor.
Qin H; Shi J; Noberini R; Pasquale EB; Song J
J Biol Chem; 2008 Oct; 283(43):29473-84. PubMed ID: 18708347
[TBL] [Abstract][Full Text] [Related]
12. Bromocriptine methylate suppresses glial inflammation and moderates disease progression in a mouse model of amyotrophic lateral sclerosis.
Tanaka K; Kanno T; Yanagisawa Y; Yasutake K; Hadano S; Yoshii F; Ikeda JE
Exp Neurol; 2011 Nov; 232(1):41-52. PubMed ID: 21867702
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effects of JGK-263 in transgenic SOD1-G93A mice of amyotrophic lateral sclerosis.
Ahn SW; Jeon GS; Kim MJ; Shon JH; Kim JE; Shin JY; Kim SM; Kim SH; Ye IH; Lee KW; Hong YH; Sung JJ
J Neurol Sci; 2014 May; 340(1-2):112-6. PubMed ID: 24680562
[TBL] [Abstract][Full Text] [Related]
14. Development and structural analysis of a nanomolar cyclic peptide antagonist for the EphA4 receptor.
Lamberto I; Lechtenberg BC; Olson EJ; Mace PD; Dawson PE; Riedl SJ; Pasquale EB
ACS Chem Biol; 2014 Dec; 9(12):2787-95. PubMed ID: 25268696
[TBL] [Abstract][Full Text] [Related]
15. Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
Milanese M; Giribaldi F; Melone M; Bonifacino T; Musante I; Carminati E; Rossi PI; Vergani L; Voci A; Conti F; Puliti A; Bonanno G
Neurobiol Dis; 2014 Apr; 64():48-59. PubMed ID: 24361555
[TBL] [Abstract][Full Text] [Related]
16. A novel mouse model with impaired dynein/dynactin function develops amyotrophic lateral sclerosis (ALS)-like features in motor neurons and improves lifespan in SOD1-ALS mice.
Teuling E; van Dis V; Wulf PS; Haasdijk ED; Akhmanova A; Hoogenraad CC; Jaarsma D
Hum Mol Genet; 2008 Sep; 17(18):2849-62. PubMed ID: 18579581
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of Nanobodies targeting the EphA4 receptor.
Schoonaert L; Rué L; Roucourt B; Timmers M; Little S; Chávez-Gutiérrez L; Dewilde M; Joyce P; Curnock A; Weber P; Haustraete J; Hassanzadeh-Ghassabeh G; De Strooper B; Van Den Bosch L; Van Damme P; Lemmens R; Robberecht W
J Biol Chem; 2017 Jul; 292(27):11452-11465. PubMed ID: 28526745
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation.
Peviani M; Salvaneschi E; Bontempi L; Petese A; Manzo A; Rossi D; Salmona M; Collina S; Bigini P; Curti D
Neurobiol Dis; 2014 Feb; 62():218-32. PubMed ID: 24141020
[TBL] [Abstract][Full Text] [Related]
19. Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis.
Jiang HQ; Ren M; Jiang HZ; Wang J; Zhang J; Yin X; Wang SY; Qi Y; Wang XD; Feng HL
Neuroscience; 2014 Sep; 277():132-8. PubMed ID: 24699224
[TBL] [Abstract][Full Text] [Related]
20. Fragment based lead discovery of small molecule inhibitors for the EPHA4 receptor tyrosine kinase.
van Linden OP; Farenc C; Zoutman WH; Hameetman L; Wijtmans M; Leurs R; Tensen CP; Siegal G; de Esch IJ
Eur J Med Chem; 2012 Jan; 47(1):493-500. PubMed ID: 22137457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
